Press release
October 18, 2018
Enzymatica signs agreement for the Japanese market
Enzymatica has entered into an agreement with a large Japanese pharmaceutical company regarding registration, marketing, distribution and sales of ColdZyme Mouth Spray for common cold.The agreement provides Enzymatica with access to one of the world's largest health care markets, with a population of about 127 million and a cough and cold market with annual sales of almost SEK 10 billion. The agreement is an important component in Enzymatica's growth strategy for international expansion.
The agreement with the Japanese pharmaceutical group provides Enzymatica with access to between 5,000 and 10,000 pharmacies, as well as up to 17,000 drugstores to sell ColdZyme in the Japanese market. The Japanese distributor will be responsible for registration, marketing, distribution and sales of ColdZyme, which will probably be sold under a local brand together with the ColdZyme brand. Access to the Japanese market is conditioned upon approval by the regulatory authorities, with expected launch in 2020. The agreement has been reached in close cooperation with Takanawa Pharma K.K., a Japanese corporation specialized in life science business.
"We are extremely pleased about the agreement, which provides us with access to one of the largest health care markets in the world. Our partner is a well-established pharmaceutical company in Japan and through them we will gain access to a large number of pharmacies and drugstores," says Fredrik Lindberg, CEO of Enzymatica.
The Japanese cough and cold market is estimated at USD 1.1 billion, which is the equivalent of about SEK 10 billion, and the total market for over-the-counter (OTC) products is estimated at USD 3.9 billion, or about SEK 35 billion. ColdZyme has no direct competitor on the market at this time, though there are various types of mouth spray that are similar products with a barrier function.
The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 7:30 CET on 18 October, 2018.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46-708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com (mailto:fredrik.lindberg@enzymatica.com)
About Takanawa Pharma K.K.
Takanawa Pharma K.K. (www.takanawa.is (http://www.takanawa.is)) is a Japanese corporation in life science business, specialized in partnering with Japanese companies for new product development.
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company's first product is ColdZyme Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in about ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North. For more information, visit: www.enzymatica.com (http://www.enzymatica.com).
Enzymatica's certified advisor is Erik Penser Bank.
Enzymaticas Certified Adviser är Erik Penser Bank.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire
